secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2026-08-25T20:05:29+00:00
Accession:  0001213900-26-093512
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyome Q2 2026 net loss $0.7M; advances VT-1953 FDA plan, in-licenses JAK inhibitors
--------------------------------------------------------------------------------

- Net loss of $720K ($0.10/share) for Q2 2026; cash $7.9M vs $5.0M at Dec 31, 2025.
- Received FDA written response on VT-1953 pivotal study strategy; plans Type C meeting.
- In-licensed two selective JAK inhibitor assets from Impetis Biosciences for autoimmune conditions.
- Granted Chinese patent for VB-1953 topical gel formulation and therapeutic acne claims.
- Phase 2 VT-1953 data showed significant malodor/pain reductions with no treatment-emergent AEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/0001213900-26-093512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/ea0303228-8k_vyome.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-093512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer